Introduction: In critically ill patients, Transfusion Related Acute Lung Injury (TRALI) remains the leading cause of transfusion-related fatalities in critical care setting and associated with inflammation and oxidative stress state. Recent research raised the potential efficacy of high dose intravenous ascorbic acid in critically ill patients. Objective: The aim of this trial was to investigate the effect of high dose intravenous ascorbic acid (VC) as a targeted therapy for TRALI in terms of serum proinflammatory (interleukin-8, interleukin-1β, C-reactive protein), anti-inflammatory (interleukin-10), oxidative stress (superoxide dismutase, malondialdehyde) markers, and plasma VC levels. Secondary outcomes were oxygenation (PaO2/FiO2 ratio), vasopressor use, duration of mechanical ventilation, ICU length of stay, 7-days mortality and 28-days mortality. Methods: Eighty critically ill patients with TRALI (n=80) were randomized to receive 2.5gm/6hr intravenous vitamin C for 96 hours (ASTRALI group) or placebo. Patients were followed-up to measure the outcomes initially (T0) and at the end of treatment (T96). Results: When compared to control group, ASTRALI group at T96, showed significantly higher median of interleukin-10 (31.6 ± 25.8 Vs. 17.7 ± 12.0 pg/mL, p<0.0001) levels and superoxide dismutase (12876 ± 4627 U/L Vs. 5895 ± 6632 U/L, p<0.0001) activities, lower median C-reactive protein (76 ± 50 Vs. 89 ± 56 mg/L, p=0.033), interleukin-8 (11.8 ± 7.3, 35.5 ± 19.8 pg/mL, p<0.0001), and malondialdehyde (0.197 ± 0.034 Vs. 0.234 ± 0.074 µM/L, p=0.002) levels. Conclusion: High dose ascorbic acid was associated with significantly reduced oxidative stress, reduced pro-inflammatory markers except IL-1β, elevated anti-inflammatory marker, and elevated plasma VC levels

Background: Risk factors for hepatitis C complication including diabetes and hypertension have seen in a many previous studies. This made the need for prompted interest in prevention through the identifying individuals at risk for these risk factors and increased investment in screening by pharmacist. Objectives: The aim of this study is to screen for several risk factors include (age, sex, BMI, Hypertension, diabetes and obesity) in HCV positive (1959) Egyptian patients. Setting: Prospective cross sectional study from September 2018 to February 2019. A total of 1959 medical records were collected. By comparing the patient characteristics, variables related to metabolic risk and body composition measured. Regression models were built to adjust for possible confounding factors. Results: The positive HCV antibody prevalence rate was 41.0 % in men and 59.0 % in women. The variables included in regression analysis are age, BMI, uncontrolled HTN were statistically significant (P < 0.001) with DM in HCV positive cases. HCV Patients with high BMI with age ≥40 (years) associated significantly with diabetes and HTN (p<0.001). Hypertensive HCV Egyptian patients were significantly associated with sex, age >40 and DM (p< 0.001). Conclusion HCV infection and metabolic disorders spin in a closed cycle relationship. Reducing the complications of DM has a promising future of limiting the complications of HCV.